MINNEAPOLIS / ST. PAUL (May 1, 2008) — More than 90 percent of children and young adults who survive five years or longer after diagnosis and treatment for acute myeloid leukemia (AML) are alive 20 years later and leading productive lives, according to a study by a cancer researcher with the Masonic Cancer Center, University of Minnesota. On a cautionary note, the study reports these survivors need to be regularly evaluated and treated for health problems that may occur later in life as a result of their initial cancer and its treatment.
These are the main findings of the largest, most comprehensive study to analyze 20 years of follow-up on survivors who were diagnosed and treated for AML as children and young adults. The findings are published today (May 1, 2008) in the journal Cancer.
Daniel Mulrooney, M.D., a pediatric oncologist and researcher at the University of Minnesota's Medical School and Masonic Cancer Center, led the research team on this study. "The favorable survival rates indicate the progress that has been made in the diagnosis and treatment of AML in children and young adults," Mulrooney said. "However, health issues occurring later in life remain an area of concern. It is crucial that these survivors continue to be evaluated in a long-term, follow-up clinic where a physician familiar with the unique issues of cancer survivors can review their previous treatment and screen for late effects of that treatment."
Leukemias are the most common cancer affecting children and young adults. AML, a cancer of the blood and bone marrow, accounts for about 25 percent of all childhood leukemias. Significant research advances at the University of Minnesota and other cancer centers over the past 30 years have resulted in better treatments and dramatically improved survival rates. But limited information exists about the medical and social outcomes of the children and young adults aggressively treated for AML.
The University of Minnesota study is the first to analyze, over the long term, the survival, medical late effects, marriage, education, and employment rates of AML survivors compared with a control group of their siblings. Mulrooney and his colleagues evaluated 272 AML survivors enrolled in the Childhood Cancer Survivor Study (CCSS).
All of the survivors evaluated had survived at least five years from the time of their diagnosis. They were younger than 21 years of age when diagnosed, were treated between 1970-1986, and did not receive a blood or bone marrow transplant. Fifty-six percent of the survivors had received only chemotherapy treatment, and 34 percent were treated with both chemotherapy and radiation.
Among these survivors, 97 percent were living 10 years after their treatment for AML, and 94 percent were living 20 years later. Six survivors reported recurrences of AML. Two survivors died from the disease, one from congestive heart failure, and one from a heart attack. The rate of AML recurrence was 1.8 percent at 10 years and 3.7 percent at 20 years.
As for their social, education, and employment outcomes, the study found:
· Marriage rates among AML survivors 25 years of age and older were similar to the general U.S. population at 57 percent, but lower than the sibling group at 67 percent.
· 40 percent of the AML survivors graduated from college compared with 52 percent of siblings and 34 percent of the general U.S. population.
· 93 percent of the survivors and 98 percent of the siblings were employed, and 92 percent of the survivors reported having health insurance compared to 89 percent of the siblings.
Mulrooney also is medical director of the University's
Long-Term Follow-Up Clinic. He worked with these colleagues to conduct this study: Douglas C. Dover, M.Sc., Suwen Li, M.S., and Yutaka Yasui, Ph.D., University of Alberta in Canada;
Joseph Neglia, M.D., University of Minnesota, Minneapolis; Charles A. Sklar, M.D., Memorial Sloan-Kettering Cancer Center in New York; Ann Mertens, Ph.D., Emory University, Atlanta; ; Kirsten Ness, Ph.D., and Leslie L. Robison, Ph.D., St. Jude Children's Research Hospital, Memphis, Tenn.; and Stella Davies, M.D., Ph.D., Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
This study was funded by the National Institutes of Health, the American Lebanese Syrian Associated Charities (ALSAC) support to St. Jude Children's Research Hospital, and the Children's Cancer Research Fund support to the Masonic Cancer Center, University of Minnesota.
The Masonic Cancer Center, University of Minnesota, is part of the University's Academic Health Center. It is a Comprehensive Cancer Center designated by the National Cancer Institute. For more information about the Masonic Cancer Center, call the information line at 612-624-2620 or toll-free in Minnesota, Iowa, Wisconsin, and the Dakotas at 1-888-CANCER MN (1-888-226-2376), or visit the Web at
www.cancer.umn.edu 
